Search results
Showing 91 to 105 of 146 results for pneumonia
This guideline covers the general principles for managing intravenous (IV) fluid therapy in hospital inpatients aged 16 and over with a range of conditions. It aims to help prescribers understand the optimal amount and composition of IV fluids to be administered and the best rate at which to give them, to improve fluid prescribing and outcomes among people in hospital. It does not cover pregnant women, and those with severe liver or renal disease, diabetes or burns.
Placement of pectus bar for pectus excavatum (also known as MIRPE or the Nuss procedure) (IPG310)
Evidence-based recommendations on placement of pectus bar for pectus excavatum (Nuss procedure). This involves placing one or two steel (pectus) bars under the breastbone with the aim of raising it and correcting the abnormal shape.
View recommendations for IPG310Show all sections
Sections for IPG310
This quality standard covers the management of Parkinson’s disease in adults. It does not include treatment of parkinsonism not caused by Parkinson’s disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS164Show all sections
Sections for QS164
- Quality statements
- Quality statement 1: Point of contact with specialist services
- Quality statement 2: Information about impulse control disorders
- Quality statement 3: Referral to physiotherapy, occupational therapy or speech and language therapy
- Quality statement 4: Levodopa in hospital or a care home
- Quality statement 5: Access to clozapine for treating hallucinations and delusions
- About this quality standard
This guideline covers diagnosing and managing atopic eczema in children under 12. It aims to improve care for children with atopic eczema by making detailed recommendations on treatment and specialist referral. The guideline also explains how healthcare professionals should assess the effect eczema has on quality of life, in addition to its physical severity.
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)
Evidence-based recommendations on pomalidomide (Imnovid) for multiple myeloma previously treated with lenalidomide and bortezomib in adults.
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
Meningitis (bacterial) and meningococcal disease: recognition, diagnosis and management (NG240)
This guideline covers recognising, diagnosing and managing bacterial meningitis and meningococcal disease in babies, children, young people and adults. It aims to reduce death and disability by helping healthcare professionals recognise meningitis and treat it quickly and effectively.
Chronic obstructive pulmonary disease (acute exacerbation): antimicrobial prescribing (NG114)
This guideline sets out an antimicrobial prescribing strategy for acute exacerbations of chronic obstructive pulmonary disease (COPD). It aims to optimise antibiotic use and reduce antibiotic resistance.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection
Evidence-based recommendations on transcervical extracorporeal reverse flow neuroprotection for reducing the risk of stroke during carotid artery stenting in adults. This involves reversing blood flow away from the brain and filtering the blood to remove any debris.
View recommendations for IPG561Show all sections
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.
This evidence summary has been withdrawn because the product is no longer available in the UK.